Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, transitioned from investment banking to biotech leadership, bringing a wealth of experience from venture capital. She discusses the challenges in developing treatments for rare diseases, including patient recruitment and trial design complexities. Renée highlights the necessity of innovative regulatory strategies for expedited market access, the importance of a cohesive corporate culture in a global company, and how curiosity fuels success in the fast-paced biotech landscape.